Stay updated with breaking news from Polypid Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript February 14, 2024 PolyPid Ltd. misses on earnings expectations. Reported EPS is $-3.97 EPS, expectations were $-2.17. PolyPid Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greeting morning and welcome to […]
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash Runway
PolyPid (NASDAQ:PYPD – Get Free Report) and Assure (NASDAQ:IONM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings. Risk and Volatility PolyPid has a beta of 1.45, […]
Shares of Applied Therapeutics, Inc.
Former Biogen CEO Michel Vounatsos Joins Quris-AI Board; Yossi Ben Amram Appointed President as BioAI Innovator Continues to Expand...